"Prudent" vitamin supplement users should limit potency to 100% RDA -- ADA.
NON-VITAMIN SUPPLEMENTS "MAY BE MORE FRAUD THAN FACT," ADA opines in its new Complete Food & Nutrition Guide, authored by registered dietitian Roberta Larson Duyff. Many supplement products, the American Dietetic Association book says, including "herbal remedies, amino acids, enzymes, plant extracts, other botanicals, and concentrates...don't provide the benefits they claim. Others may have harmful side effects. Some may be more fraud than fact." The book was introduced at ADA's 79th annual meeting, held Oct. 21-24 in San Antonio, Tex.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges